chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At time of injection, a significant portion of the vaccine spurted out of my skin and ran down my arm, the following morning there was a large lump under the injection site that was soft, movable and painful, also there was a slight rash around the injection site, after some squeezing and itching, the lump became hard and painful, the rash covered more area of the arm and the pain spread under the arm to the lymph nodes.
Woke up on 11/23/22  around 8:30 am with abdominal cramps at the lower left abdomen. At around 11:45 pm Entered ER on  the evening of 11/23/2022 with severe lower left side abdominal pain and nausea. After CT scan it was confirmed I had diverticulitis - was prescibed Cipro, Metronidazole and Norco for pain. All liquid diet the. A low residue diet until better. 10 day course of antibiotics.
I tested positive for COVID-19 on 6/21/22.  Spoke to my doctor on 6/22/22 and received paxlovid.  Took  medication and feel fine now.
Per report from family member illness started with fever, chills and increasingly progressed to needing emergency care
Pt. received Tdap vaccine on 10/22/12 and next day developed a rash at site of injection, edema, tenderness, and warm. Pt. also c/o chills, nausea and temp 100.1 due to vaccine. Reports she was fine before the vaccine. Pt. was treated with BENADRYL, Loratadine, Prednisone and KEFLEX.
Breakthrough case admission after 2 vaccines  Janssen 4/10/21 Lot# 041A;  Moderna 12/19/21 Lot# 068H21A
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. On 03-AUG-2013 the patient was vaccinated with ZOSTAVAX (lot # J002777, expiration date 07-JUN-2014) injection, subcutaneous. On an unknown date the patient experienced injection site reaction after receiving ZOSTAVAX that was described to be like a "big welt or target" that itched but was not reported to have been a rash. The pharmacist stated that other patient was vaccinated with vial sharing the lot number (MARRS 1308USA010307). The outcome of injection site reaction and injection site itching was unknown. The causality was unknown. This is one of several reports from the same source (MARRS 1308USA010306. 1308USA006743 and 1308USA010307). Additional information has been requested.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 30 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 24Sep2021 (Batch/Lot number: unknown) at the age of 30 years as dose 1, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: FEELING COLD (non-serious) with onset 2021, outcome "unknown", described as "I am freezing cold"; PAIN (non-serious) with onset 2021, outcome "unknown", described as "Body is aching so bad like it is hard to get out/I am in too much pain inside"; HEADACHE (non-serious) with onset 2021, outcome "unknown", described as "Headache"; MYALGIA (non-serious) with onset 2021, outcome "unknown", described as "My muscles are sore"; MOVEMENT DISORDER (non-serious) with onset 2021, outcome "unknown", described as "I can barely get up/hard to get out". Additional information: Vaccination second dose scheduled on 15Oct2021. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Soreness, mild numbnes/which radiates to L lower arm weakness and left scapular area. Given at workplace.
Blood pressure prior to vaccine  was 135/80, day after patient checked his blood pressure and it was 200/150.  Currently working with healthcare facility to reduce blood pressure.  EKG and blood work have been done to eliminate any other causes to the increase of the blood pressure
Information has been received from a nurse concerning a male with asthma and no drug reactions/allergies, who on 08-SEP-2009 was vaccinated with the first 0.5 ml dose of PNEUMOVAX 23 (lot # 661897/1333X) by intramuscular route. The patient experienced fever, nausea, chills and a "welt" at the injection site a few hours after receiving the vaccine. Additionally, the patient began vomiting and developed a photosensitivity and a bad headache on 09-SEP-2009, last pm. At the time of the report all the patient's symptoms persisted. The patient was seen by the medical Director of the travel clinic on 10-SEP-2009 and was given an antiemetic for vomiting. The patient was due to return to the clinic on 11-SEP-2009 for follow up. No laboratory tests were performed. This is one of two reports received for the same source. Follow up information was received from a physician via medical records concerning a healthy 27-year-old non-smoker male with asthma, mild environmental allergies, alcohol use (3 alcoholic beverages per week) and no medication allergies and no illicit drug use and a history of hospitalization for suspected appendicitis (no surgery required) who on 08-SEP2009 was vaccinated SC into the left deltoid with first dose of PNEUMOVAX 23 (lot number 661897/1333X) and third dose of rabies vaccine (manufacturer unknown) at the same site (left deltoid). Concomitant therapy included CLARITIN, albuterol, FLONASE. It was reported that the patient did well at that time and was released to return home. That night, on 08-SEP-2009, the patient began developing significant local reaction at the injection site. He reported fevers as well as some sweats, felt overall poorly, and described myalgias and a headache. He attempted to work on 09-SEP-2009, but was forced to return home where he continued with nausea and vomiting and generally feeling poorly. He contacted the office and was promptly seen. The patient was seen at the office on 10-SEP-2009. The vital signs were: Blood pressure 124/79, pulse 98 regular, respirations 16 and unlabored, temperature 100. On 11-SEP-2009, the patient came to the office for a follow up visit. He reported high temperature (101) with drenching sweats last night (on 10-SEP-2009). The patient had relief of nausea and vomiting with PO odansetron. The patient was taking oral liquids and bland foods. It was reported that the injection site reaction, erythema, myalgias and headache had lessened and improved. There was no evidence of cellulitis. Non-Steroid Anti-Inflammatory Drug (NSAID) and acetaminophen were prescribed. It was reported that the patient was planned to continue with symptomatic treatment. The patient's vital signs in this visit were: Blood pressure 121/71, pulse and temperature of 98.4. The patient recovered from the events on an unspecified date. No further information is available.
ALWAYS SICK; This spontaneous report received from a parent via a company representative concerned an adult of unspecified sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced always sick. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from always sick. This report was non-serious.
Patient had fatigue and 104 fever with confusion less than 24 hours after Td vaccination.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, drug reactions, allergies or concomitant therapies provided. On 12-DEC-2016, the patient was vaccinated with improperly stored dose of PROQUAD lot # M021731 with expiration date 29-OCT-2017 (dose and route of administration were not reported). The reason of the call was temperature alarm received via a Digital Data Logger. It was reported that the vaccine was exposed to temperature of -14.4 degrees Celsius for 54 minutes before administration to the patient. No previous temperature excursion was reported. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information is not expected, all information has already been obtained.; Sender's Comments: US-009507513-1611USA004113: US-009507513-1611USA011831: US-009507513-1705USA009742:
Rash on the medial aspect of the bicep; Erythma at the injection site; This case was reported by a physician via call center representative and described the occurrence of rash in a 69-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In October 2019, the patient received the 1st dose of Shingrix (intramuscular). In October 2019, less than a day after receiving Shingrix, the patient experienced rash and injection site erythema. On an unknown date, the outcome of the rash and injection site erythema were recovered/resolved.   It was unknown if the reporter considered the rash and injection site erythema to be related to Shingrix.  Additional information was received as follows: The patient received Shingrix on right deltoid and on the same day the patient developed a rash on the medial aspect of the bicep and erythema at the injection site. The events spontaneously resolved after 3 days. The reporter did consented for follow up.
now experiencing hair loss even more this morning, whole braid came out; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (now experiencing hair loss even more this morning, whole braid came out) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     Concurrent medical conditions included Rheumatoid arthritis and Pre-diabetic. Concomitant products included METFORMIN for Diabetic, PARACETAMOL (TYLENOL [PARACETAMOL]) for Pain, LEFLUNOMIDE for Rheumatoid arthritis, HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL/HCTZ), AMITRIPTYLINE, COLECALCIFEROL (VITAMIN D3), CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]), BIOTIN and VITAMIN C [ASCORBIC ACID] for an unknown indication.    On 13-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In December 2021, the patient experienced ALOPECIA (now experiencing hair loss even more this morning, whole braid came out). At the time of the report, ALOPECIA (now experiencing hair loss even more this morning, whole braid came out) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient experiencing hair loss. she started noticing it a couple of days ago and even more this morning. Her natural hair is braided. Her whole braid came out.  No treatment information details were reported.
About a month after the vaccine I developed extreme fatigue, the right area of my thyroid swole resulting in me visiting my PCP. Bloodwork was performed and my Thyroid TPO antibiotics was elevated and the PCP ordered an ultrasound of my Thyroid where multiple modules were found. I had a biopsy done and the right more larger painful nodule one was diagnosed as Granulomatous Thyroiditis and the left module was diagnosed as Hashimoto's Disease. I was prescribed Naltraxone to help with the symptoms and still to date I still have symptoms as a result of both diseases.
This non-serious spontaneous case, initially received from other non-health professional on 13-Nov-2018, concerns a 67-year-old, elderly patient of an unspecified gender. It was reported that, the FLUAD (TIV) vaccine underwent temperature excursion for the first time. The vaccine was out for around 48 hours and it reached 11.6 degree Celsius. On 12-Oct-2018, the patient was administered FLUAD (TIV) [batch number: 250795, dose, route of administration, anatomical location and expiry date: not reported] which underwent temperature excursion. At the time of this report, no adverse event was reported. This case 201805525 was crossed linked to original cases 201804863 due to same reporter.
Expired vaccine used; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 22-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication reported. No treatment information was provided.
Patient developed chest tightness/pain with associated shortness of breath and bilateral lower leg numbness on 9/10/09.  Symptoms persisting but not progressing as of 9/14/09 office visit.  Good muscular strength making Guillan Barre not likely.  Being referred to Neurology for further evaluation
Child received a 2nd dose of FluMist, and child should have only received 1 dose due to age. Child is 9 years old.  No treatment. Per child's father, child had no symptoms after administration of 2nd dose. Was notified of error.
It was a little bit of a sore throat; more tight than raw feeling. Nasal and sinus congestion, some sneezing and coughing, I never had a fever. At the urgent care they prescribed 5 day course of PAXLOVID and I started it on Friday 12/2.
This spontaneous report has been received from a nurse and refers to a 12 month old male patient. No information was provided regarding the patient's medical history, concurrent conditions, drug reactions, allergies or concomitant medications. On 21-DEC-2017, the patient was vaccinated with a dose of VARIVAX intramuscularly for prophylaxis, lot # N010108 (dose and expiration date were not reported). The same day, the patient  was vaccinated with a dose of M-M-R II intramuscularly for prophylaxis, lot # N008366 (dose and expiration date were not reported). At the time of vaccination there was not illness or pre-existing physician-diagnosed allergies, birth defects or medical conditions. There was not adverse event involved or product quality complaint.
fever; headache; fever; chills; headache; general fatigue; This spontaneous case was reported by a consumer and describes the occurrence of the first episode of PYREXIA (fever), CHILLS (chills), the first episode of HEADACHE (headache), FATIGUE (general fatigue) and the second episode of PYREXIA (fever) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Apr-2021, the patient experienced the first episode of PYREXIA (fever), CHILLS (chills), the first episode of HEADACHE (headache) and FATIGUE (general fatigue). On 14-Apr-2021, the patient experienced the second episode of PYREXIA (fever) and the second episode of HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 11-Apr-2021, CHILLS (chills) and FATIGUE (general fatigue) had resolved. At the time of the report, last episode of PYREXIA (fever) and the last episode of HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100.9f (abnormal) 100.9F.         Concomitant medications reported were, blood pressure medicine, thyroid medicine, cholesterol lowering medicine.  Action taken with mRNA-1273 in response to the events was not applicable
fatigue; nausea; brain fog; body weakness; This is a spontaneous report from a contactable consumer. A 69-year-old female patient received dose 1 of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number EN6199) via an unspecified route of administration on 04Mar2021 at 14:45 (at the age of 69-years-old) as a single dose in the left arm for COVID-19 immunization. Medical history included chronic fatigue, depression, sleep disorder, anxiety, possibly other chronic and acute disease, and allergic to wheat or wheat product. The patient was not pregnant at the time of vaccination. The patient had not received any other vaccines within 4 weeks prior to the vaccine. The patient was not diagnosed with COVID-19 prior to the vaccine. Concomitant medications included sleep medications, antidepressants, cetirizine (ZYRTEC), acyclovir, ibuprofen, and "multivitamins - B, C, E, biotin, psyllium, selenium, alpha lipolic acid, folate, magnesium (Mg), potassium (K)." On 04Mar2021 at 18:00, within 3 or 4 hours the patient experienced fatigue, brain fog, nausea, and body weakness. The patient was not hospitalized for the events. The patient visited a doctor or other healthcare professional office/clinic as a result of the events. The patient was treated with calcium carbonate (TUMS) for nausea. The outcomes of fatigue, brain fog, nausea, and body weakness were recovering. It was also reported that since the vaccine, the patient had not been tested for COVID-19.   No follow-up attempts are needed. No further information is expected.
Patient had a vasovagal episode. No LOC. Patient has a past history of fainting when getting injections.
I began to  have shortness of breath two days  after receiving the first dose of COVID. This lasted a week. I went to the doctors and they did not have any other answer except "anxiety". I was given Propranolol for anxiety but it did not help with my breathing at all.  After a week, I was back to feeling like myself. However, I just got the 2nd dose of vaccine and the shortness of breath is back and shows no signs of stopping. It has been over a week since I've had these symptoms. I know for a fact this is not anxiety, it is something physical.
Swelling of vocal chords followed by need to blow nose which caused bleeding and clotting in nostrils.; Swelling of vocal chords followed by need to blow nose; Swelling of vocal chords followed by need to blow nose which caused bleeding and clotting in nostrils.; Causes constant congestion.; crusted scabs from nose for over two week timeframe.; This is a spontaneous report from a contactable consumer (patient). An 81-year-old female patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number; EL9264), via an unspecified route of administration administered in left arm on 09Feb2021 as SINGLE DOSE for COVID-19 immunisation. The patient was not pregnant at the time of vaccination. The patient had no COVID prior to vaccination. Medical history included osteoarthritis, osteoporosis, neuropathy, hypothyroidism, thyroidectomy, hysterectomy, and two recent falls. The patient had no known allergies. Concomitant medication included influenza vaccine (FLU) taken for immunisation. Historical vaccine includes first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: EL3249) on 19Jan2021 at 04:30 PM administered in the right arm for COVID-19 immunization. The patient experienced swelling of vocal chords followed by need to blow nose which caused bleeding and clotting in nostrils. The patient was constantly blowing up bloody clots/crusted scabs from nose for over two week timeframe. At first, was a lot of clots, red blood and scabs. It got better over 14 days, but, still persists. Now clots and scabs are smaller but still frequent. Causes constant congestion. All events started on 05Mar2021 at 12:00 AM. The events resulted in doctor or healthcare professional visit/clinic visit. There was no treatment received for all events. The patient was COVID tested (nasal swab) post vaccination on 09Mar2021 which was negative. The patient had not yet recovered from all events.
Patient stated arm was sore approximately 3 days after injection given.  Site was getting better until morning of 07/20/2020 where it flaired up and was sore.  Patient does not have a primary MD but recomended if it continues to hurt or worsen to go to Urgent Care or ER.  Patient states no fever or inflanmation.  I am asking patient to follow up with me in a few days.  Confirmed proper technique was used(proper site and form) upon speaking with patient.
Information has been received from a nurse practitioner, concerning a 23 year old female patient, with a vaginal yeast infection (unspecified) who on 19-APR-2010, was vaccinated intramuscularly with a dose of GARDASIL (dose, and lot number not provided) at a clinic. It was unknown if it was the first dose of GARDASIL. Concomitant therapy included DIFLUCAN for the vaginal yeast infection. It was reported that DIFLUCAN was taken three hours after the vaccine was administered on 19-MAR-2010. On 20-APR-2010, the patient experienced groin swelling. On 23-APR-2010, the patient sought medical attention through the nurse practitioner. The nurse practitioner stated that the administration of DIFLUCAN may or may not contributed to the groin swelling and prescribed KEFLEX, BENADRYL and ibuprofen. On 26-APR-2010, the patient was seen again and the groin swelling had resolved. No further information is available.
A 15 yrs 11 month old female student looked pale, sweating, felt nauseous after receiving the four vaccines. She is assisted to lay down on the floor with her feet elevated. O2 5 liters given. Vital signs taken: 2:35pm: BP 122/85, HR 84, RR 16,O2 sat 100% 2:37pm: BP 121/91, HR 93, RR 16, O2 sat 99%, Color pink, no nausea or dizziness, no shortness of breath 2:40pm: BP 121/84, HR 84, RR 20, O2 sat 99% 2:42pm:BP (sitting) 101/66, HR 87, RR 20, O2 sat 100%, denied dizziness 2:45pm:BP (sitting) 118/66, HR 64, RR 20, O2 sat 100% on room air. 2:50pm: BP(Sitting) 103/67, HR 68, RR 20, O2 sat 98% 2:55pm BP(Sitting) 107/64, HR 69, RR 16, O2 sat 99% 3:00pmBP(Standing) 97/61, HR 81, RR 16 O2 sat 100%, denied dizziness 3:05pm BP (Standing) 113/69, HR 69, RR 16, O2 sat 100% She is awake and responds to verbal stimuli the whole time. Student went home with her mother and guardian. Refer to seek medical care for difficulty breathing  and chest tightness. Mother and guardian understand the instructions.
Parents brought pt in 5 days after imms. stating the night imms. rec'd she broke out with a rash. her visit on 8/6/13 pt has hives arms, legs, trunk - parents state the resolve in one area and pop up in another area. Welts are raised, pink-not itchy. Rx-OTC BENADRYL. Other possible causes discussed ie food, clothing, bug bites.
Following well child visit and vaccinations 9/2021 developed higher fever along with developing profound fatigue, decreased energy, and headache whose only positive test was initially for rhinovirus/enterovirus on 10/5 done in the setting of fevers, who has had since that time a variable/waxing-waning course with most prominent symptoms of fatigue (and some reported post-exertional malaise), ongoing intermittent temperatures/fevers (100s-103s) with many repeated inflammatory lab checks both during and between fevers (ESR/CRP/CBC) which have been normal, and more recently with issues of back pain and shin pain who overall has findings and negative studies suggestive of CFS/ME like illness.